Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412477 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00412477 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 18 participants.
The verdict
NCT00412477, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To evaluate the safety of LFn-p24 administered at three different doses with Alhydrogel given intramuscularly To evaluate immune responses to LFn-p24 with Alhydrogel at three different doses given intramuscularly
Interventions
- BIOLOGICAL HIV LFn-p24
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-08-20 |
| Est. Completion | 2006-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412477
The ClinicalTrials.gov registry entry for NCT00412477 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HIV LFn-p24 is the first listed.
NCT00412477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412477 about?
NCT00412477 is a clinical study titled "A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine". To evaluate the safety of LFn-p24 administered at three different doses with Alhydrogel given intramuscularly To evaluate immune responses to LFn-p24 with Alhydrogel at three different doses given intramuscularly
What is the current status of trial NCT00412477?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-08-20. Estimated completion is 2006-11-01.
What interventions are being tested in trial NCT00412477?
The interventions under investigation include: HIV LFn-p24 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00412477?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.